Company Overview and News

MIDF Research sees last-mile delivery players, e-commerce platforms in DFTZ

2018-10-19 theedgemarkets
KUALA LUMPUR (Oct 19): MIDF Amanah Investment Bank Bhd Equity Research has maintained its "neutral" rating (NR) on the logistics sector, and said it does discount the possibilities of last-mile delivery players and e-commerce platforms participating in the Digital Free Trade Zone (DFTZ).
0078 7117 5267 7210

Stock With Momentum: Freight Management Holdings

2018-08-24 theedgemarkets
Freight Management Holdings Bhd (-ve) TRADING of shares in Freight Management Holdings Bhd (fundamental: 1.4/3, valuation: 2/3) also triggered our momentum algorithm yesterday for the first time this year.

Freight Management 4Q net profit falls 29%, pays 3.5 sen dividend

2018-08-21 theedgemarkets
KUALA LUMPUR (Aug 21): Freight Management Holdings Bhd’s (FMHB) net profit fell 28.5% to RM4.17 million in the fourth financial quarter ended June 30, 2018 (4QFY18) from RM5.82 million a year ago, mainly due to share of losses of associate in Singapore-based TCH Marine Pte Ltd and impairment of advances in a joint venture.

KLCI starts on flat note, bright debut for Radiant Globaltech

2018-07-24 theedgemarkets
KUALA LUMPUR (July 24): The FBM KLCI started on a flat note this morning and is seen moving sideways following the mixed overnight performance at most global markets.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...